Roxanne Nelson

At the NCCN Annual Conference, Dr. Bijal Shah of Tampa’s Moffitt Cancer Center highlighted ongoing challenges in administration of CAR T-cell therapy.

During the NCCN Annual Conference, Ron Kline, MD, FAAP, from CMS’s Innovation Center, discussed the Center’s pilot Oncology Care Model.

Triple-negative breast cancer treatments being investigated include checkpoint inhibitors, agents that target the androgen receptor pathways, and antibody-drug conjugates.

PARP inhibitors are offering new treatment options for ovarian cancer patients with known mutations, but early-stage diagnosis is still elusive.

During the NCCN Annual Conference in Orlando, Dr. Peter Carroll from UCSF discussed the evolution of screening tests for prostate cancer.